Please login to the form below
Listeria monocytogenes
This page shows the latest Listeria monocytogenes news and features for those working in and with pharma, biotech and healthcare.
Advaxis shaken by another FDA hold on cervical cancer vaccine
Axal is a targeted Listeria monocytogenes (Lm)-based immunotherapy that attacks HPV-associated cancers by altering a live strain of Lm bacteria to generate cancer-fighting T cells against cancer antigens
Latest news
-
Amgen enters into $540m immunotherapy collaboration
Listeria monocytogenes (Lm) technology to create a tailored cancer treatment.
-
Listeria-based vaccine could halt breast cancer
The vaccine was developed from investigations into the Listeria monocytogenes bacterium which grows in milk, cheese and other dairy products. ... Listeria blocks the immune system's response when it gains access to the body, helping it to spread.
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Pharma deals during October 2014
on Aduro's novel LADD [live-attenuated double-deleted Listeria monocytogenes strains that have been engineered to induce an innate immune response] immunotherapy platform.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Senior Medical Writer – Medical Communications – North West – In...
-
Excellent Remuneration Package
-
Senior Copywriter
-
Salary TBC
- Senior / Principal Medical Writers wanted - MedComms - Various U...
-
Excellent Remuneration Packages
-
Account Director, Medical Education
-
Salary TBC
- Senior Account Manager / Account Director - MedComms - London
-
Highly competitive salary &package
-
Senior Medical Writer
-
Salary TBC
- Experienced / Senior Medical Writer - Excellent Progression Oppo...
-
Excellent Salary and Benefits on offer
- Editorial Assistants - Medical Communications agency - Cheshire
-
Excellent Remuneration Package
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
Subscribe to our email news alerts
- Leading AstraZeneca’s return to growth in Europe
- Eli Lilly shutters UK neuroscience unit, with 80 job losses expected
- Roche reports continued growth in Q3, despite biosimilar competition
- Takeda offloads select portfolio to Acino ahead of Shire takeover
- Bayer/J&J claim new FDA okay for clot drug Xarelto
- CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal
- The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
- Come meet Valid Insight at booth C2-006 at ISPOR Europe 2019
- Vertex scores FDA approval for CF triple therapy Trikafta
- Seattle Genetics preps filing next year for oral HER2 drug
- Novartis grows in Q3 thanks to stellar performance of key drugs
- AZ’s Farxiga gets heart failure prevention okay from FDA
PMHub
Novasecta
We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...
Latest intelligence
- The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
- The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
- Evolution or revolution: the latest review of NICE methods
- By Leela Barham...
- Integrating patient reported outcomes into clinical trials
- How capturing the patient voice is unlocking medicines’ commercial potential...
Quick links
Infographics
